Abstract |
UMP synthase (UMPS) catalyzes the last two steps of de novo pyrimidine nucleotide synthesis and is a potential cancer drug target. The C-terminal domain of UMPS is orotidine-5'-monophosphate decarboxylase (OMPD), a cofactor-less yet extremely efficient enzyme. Studies of OMPDs from micro-organisms led to the proposal of several noncovalent decarboxylation mechanisms via high-energy intermediates. We describe nine crystal structures of human OMPD in complex with substrate, product, and nucleotide inhibitors. Unexpectedly, simple compounds can replace the natural nucleotides and induce a closed conformation of OMPD, defining a tripartite catalytic site. The structures outline the requirements drugs must meet to maximize therapeutic effects and minimize cross-species activity. Chemical mimicry by iodide identified a CO(2) product binding site. Plasticity of catalytic residues and a covalent OMPD- UMP complex prompt a reevaluation of the prevailing decarboxylation mechanism in favor of covalent intermediates. This mechanism can also explain the observed catalytic promiscuity of OMPD.
|
Authors | Julia G Wittmann, Daniel Heinrich, Kathrin Gasow, Alexandra Frey, Ulf Diederichsen, Markus G Rudolph |
Journal | Structure (London, England : 1993)
(Structure)
Vol. 16
Issue 1
Pg. 82-92
(Jan 2008)
ISSN: 0969-2126 [Print] United States |
PMID | 18184586
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Multienzyme Complexes
- Uracil Nucleotides
- uridine 5'-monophosphate synthase
- Orotate Phosphoribosyltransferase
- Orotidine-5'-Phosphate Decarboxylase
|
Topics |
- Drug Design
- Humans
- Kinetics
- Models, Molecular
- Multienzyme Complexes
(chemistry, metabolism)
- Orotate Phosphoribosyltransferase
(chemistry, metabolism)
- Orotidine-5'-Phosphate Decarboxylase
(chemistry, drug effects, metabolism)
- Protein Conformation
- Uracil Nucleotides
(chemistry, metabolism)
|